مورد إلكتروني
أعرض في EDS

Quality of life measured in first-line therapy during the Cryo-FIRST study: A comparison between cryoballoon catheter ablation versus antiarrhythmic drug therapy.

التفاصيل البيبلوغرافية
العنوان: Quality of life measured in first-line therapy during the Cryo-FIRST study: A comparison between cryoballoon catheter ablation versus antiarrhythmic drug therapy.
بيانات النشر: Oxford University Press Netherlands 2021-02-18
تفاصيل مُضافة: Chen J.
Meyer C.
Iacopino S.
Kuniss M.
Anselme F.
Chierchia G.B.
Pavlovic N.
Velagic V.
Hermida J.S.
Healy S.
Arena G.
Badenco N.
نوع الوثيقة: Electronic Resource
مستخلص: Background: By consensus statements, catheter ablation is a recommended treatment for patients with symptomatic drug-refractory paroxysmal atrial fibrillation (AF), as patients try to alleviate the burdensome AF symptoms that reduce the Quality of Life (QoL). Yet, first-line treatment of symptomatic patients via catheter ablation prior to initiation of antiarrhythmic drugs (AADs) is only a reasonable alternative (Class IIa). Clearly, more clinical data is necessary that compares catheter ablation to AAD therapy in treatment naive patients. Purpose(s): The Cryo-FIRST trial was designed to compare AAD treatment against pulmonary vein isolation (PVI) while using a cryoballoon catheter (Arctic Front Advance; Medtronic, Inc.). This current data analysis examines the QoL endpoints when comparing AADs to cryoballoon ablation in patients with symptomatic treatment naive paroxysmal AF. Method(s): This randomized multicenter trial enrolled 220 patients from 18 sites in 9 countries (Europe, Australia, and Latin America) in a prospective open-blinded endpoint study design. Patients had not been administered a class I or III AAD for longer than 48 hours for inclusion into the study. Subjects were randomized (1:1) into a cohort that was administered AAD therapy or a cohort that received PVI via cryoablation. The prespecified QoL endpoint at 12 months was measured using the Atrial Fibrillation Effect on Quality of Life (AFEQT) scores, and QoL recordings were taken at baseline, 1, 3, 6, 9, and 12 months following the index treatment. Result(s): Of the 218 patients randomized (age 52+/-13 years, 68% male) 86% completed the 12-month follow-up. Crossovers occurred in 9% of subjects (N=20), including: 1 subject in the cryoablation arm and 19 subjects in the AAD arm. At 12 months, 86.5% of the patients in the cryoablation arm and 70.4% of the patients in the AAD arm where without symptoms (EHRA score 1). The mean AFEQT summary score was more favorable in the catheter ablation group comp
مصطلحات الفهرس: cohort analysis, conference abstract, controlled study, data analysis, drug therapy, Europe, female, follow up, human, major clinical study, male, middle aged, multicenter study, palliative therapy, adult, prospective study, pulmonary vein isolation, quality of life, randomized controlled trial, single blind procedure, South and Central America, antiarrhythmic agent, Australia, paroxysmal atrial fibrillation, catheter ablation, clinical trial, Conference Abstract
URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27283
LibKey Link
الإتاحة: Open access content. Open access content
Copyright 2021 Elsevier B.V., All rights reserved.
أرقام أخرى: AUSHL oai:repository.monashhealth.org:1/27283
European Heart Journal. Conference: European Society of Cardiology Congress, ESC 2020. Virtual. 41 (SUPPL 2) (pp 436), 2020. Date of Publication: November 2020.
1522-9645
https://repository.monashhealth.org/monashhealthjspui/handle/1/27283
634166896
(Chierchia) Vrije Universiteit Brussel, Postgraduate Course in Clinical ElectroPhysiology and Pacing, Heart Rhythm Management Center, Brussel, Belgium (Pavlovic) Sestre Milosrdnice University Hospital Centre, Cardiology, Zagreb, Croatia (Velagic) University Hospital Centre Zagreb, Cardiovascular Medicine, Zagreb, Croatia (Hermida) Centre Hospitalier Universitaire d'Amiens-Picardie, Service de Cardiologie Rythmologie et Stimulation Cardiaque, Amiens, France (Healy) Monash Health, Clayton, Australia (Arena) Ospedale Apuane, Cardiology, Massa Carrara, Italy (Badenco) AP-HP Sorbonne Universite, Hopital Pitie-Salpetriere, Cardiologie, Paris, France (Meyer) University Heart Center, Department of Cardiology-Electrophysiology, Hamburg, Germany (Chen) Haukeland University Hospital, Department of Heart Disease, Bergen, Norway (Iacopino) Villa Maria Cecilia, Aritmologia, Cotignola, Italy (Anselme) CHU de Rouen, Cardiologie, Rouen, France (Kuniss) Kerckhoff Heart Center, Cardiology, Bad Nauheim, Germany
(Chierchia) Vrije Universiteit Brussel, Postgraduate Course in Clinical ElectroPhysiology and Pacing, Heart Rhythm Management Center, Brussel, Belgium
(Pavlovic) Sestre Milosrdnice University Hospital Centre, Cardiology, Zagreb, Croatia
(Velagic) University Hospital Centre Zagreb, Cardiovascular Medicine, Zagreb, Croatia
(Hermida) Centre Hospitalier Universitaire d'Amiens-Picardie, Service de Cardiologie Rythmologie et Stimulation Cardiaque, Amiens, France
(Arena) Ospedale Apuane, Cardiology, Massa Carrara, Italy
(Badenco) AP-HP Sorbonne Universite, Hopital Pitie-Salpetriere, Cardiologie, Paris, France
(Meyer) University Heart Center, Department of Cardiology-Electrophysiology, Hamburg, Germany
(Chen) Haukeland University Hospital, Department of Heart Disease, Bergen, Norway
(Iacopino) Villa Maria Cecilia, Aritmologia, Cotignola, Italy
(Anselme) CHU de Rouen, Cardiologie, Rouen, France
(Kuniss) Kerckhoff Heart Center, Cardiology, Bad Nauheim, Germany
(Healy) Monash Health, Clayton, Australia
1305107694
المصدر المساهم: MONASH HEALTH LIBRS
From OAIster®, provided by the OCLC Cooperative.
رقم الأكسشن: edsoai.on1305107694
قاعدة البيانات: OAIster
الوصف
الوصف غير متاح.